Author

Vivek Subbiah

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Safety and efficacy of intratumoral MEDI1191, an IL-12 mRNA lipid nanoparticle, plus intravenous durvalumab in patients with advanced solid tumors: a first-in-human study.

PURPOSE MEDI1191 is a lipid nanoparticle-formulated mRNA designed to induce local interleukin-12 production and intensify antitumor T cell responses. We report dose-escalation results from a first-in-human, open-label, phase I study of intratumoral MEDI1191 plus intravenous durvalumab (NCT03946800). METHODS Patients...

B. Carneiro, Thomas U. Marron, Dmitriy Zamarin et al. · Clinical Cancer Research · 0 citations

Open access Aug 2026

ERK1/2 Inhibitor Ulixertinib in Pan-cancer Patients with BRAF Fusions or Non-V600E/K Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1L

Purpose: Mutations in BRAF at codons other than V600 (non-V600) and BRAF fusions confer dependence on RAF-MEK-ERK pathway. Subprotocol Z1L (EAY131-Z1L) investigated the clinical activity of ulixertinib (ERK1/2 inhibitor) in patients with tumors harboring these alterations. Patients and Methods: In this single-arm study...

Vivek Subbiah, Feng-Min Zhao, R. Kudchadkar et al. · Clinical Cancer Research · 0 citations

Jul 2026

Abstract IA010: On the right TRACK: Operationalizing a national, patient-driven, decentralized trial offering comprehensive genomic profiling and a molecular tumor board for rare cancers

Collectively, rare cancers account for approximately 20–25% of all malignancies, and the challenges faced by patients and researchers are consistent across all rare cancer tumor types. Notably, patients encounter challenges in access to clinical trials, access to biomarker testing, and access to expert interpretation...

J. Palma, Shumei Kato, M. Nikanjam et al. · Cancer Research · 0 citations